<DOC>
	<DOCNO>NCT01270035</DOCNO>
	<brief_summary>In Japan , well country , dose adalimumab ( ADA ) limit 40 mg every week use combination methotrexate ( MTX ) patient rheumatoid arthritis ( RA ) . However , ADA 80 mg MTX may require RA patient , especially high disease activity . Therefore , tried increase ADA dose 80 mg every week concomitant MTX , disease activity decrease moderate activity define DAS28 &lt; 3.2 . The primary endpoint rate patient achieve disease remission ( DAS28 &lt; 2.6 ) 30 week predifined treatment strategy .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab 80 mg Every Other Week With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>patient rheumatoid arthritis receive MTX â‰§ 6 mg/week least 3 month disease activity : DAS28 &gt; 5.1 allergy ADA present active infection include TB history demyelinate disease , HBV infection malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>